A detailed history of Empirical Asset Management, LLC transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Empirical Asset Management, LLC holds 13,300 shares of AKBA stock, worth $27,530. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,300
Previous 33,700 60.53%
Holding current value
$27,530
Previous $44,000 45.45%
% of portfolio
0.0%
Previous 0.01%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 15, 2025

SELL
$1.26 - $2.13 $25,704 - $43,452
-20,400 Reduced 60.53%
13,300 $24,000
Q3 2024

Oct 11, 2024

BUY
$0.94 - $1.55 $31,678 - $52,235
33,700 New
33,700 $44,000

Others Institutions Holding AKBA

About Akebia Therapeutics, Inc.


  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $381M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track This Portfolio

Track Empirical Asset Management, LLC Portfolio

Follow Empirical Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Empirical Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Empirical Asset Management, LLC with notifications on news.